Treace Medical Concepts, Inc. (NASDAQ:TMCI) Shares Bought by Wolverine Trading LLC

Wolverine Trading LLC grew its holdings in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 17.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,946 shares of the company’s stock after purchasing an additional 1,946 shares during the period. Wolverine Trading LLC’s holdings in Treace Medical Concepts were worth $75,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TMCI. CWM LLC increased its position in Treace Medical Concepts by 208.7% during the 2nd quarter. CWM LLC now owns 10,097 shares of the company’s stock worth $67,000 after purchasing an additional 6,826 shares during the period. Nisa Investment Advisors LLC increased its position in Treace Medical Concepts by 34,240.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 9,272 shares of the company’s stock worth $62,000 after purchasing an additional 9,245 shares during the period. Bank of New York Mellon Corp increased its position in Treace Medical Concepts by 13.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 161,413 shares of the company’s stock worth $1,073,000 after purchasing an additional 18,721 shares during the period. Bensler LLC acquired a new position in Treace Medical Concepts during the 2nd quarter worth approximately $236,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Treace Medical Concepts by 59.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,685 shares of the company’s stock worth $111,000 after purchasing an additional 6,227 shares during the period. Institutional investors and hedge funds own 84.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TMCI shares. Truist Financial dropped their target price on Treace Medical Concepts from $7.50 to $6.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $8.00 price target on shares of Treace Medical Concepts in a report on Tuesday. Finally, Stifel Nicolaus upped their price target on Treace Medical Concepts from $7.00 to $8.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $7.40.

Treace Medical Concepts Price Performance

Shares of NASDAQ:TMCI opened at $7.46 on Wednesday. The business’s fifty day moving average price is $6.83 and its two-hundred day moving average price is $6.46. The stock has a market cap of $464.45 million, a PE ratio of -7.53 and a beta of 0.66. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.98 and a current ratio of 4.12. Treace Medical Concepts, Inc. has a one year low of $3.92 and a one year high of $15.98.

Treace Medical Concepts (NASDAQ:TMCI) last announced its earnings results on Tuesday, November 5th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. The firm had revenue of $45.09 million for the quarter, compared to analysts’ expectations of $43.48 million. Treace Medical Concepts had a negative return on equity of 51.12% and a negative net margin of 30.33%. Treace Medical Concepts’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.28) EPS. On average, analysts forecast that Treace Medical Concepts, Inc. will post -0.92 EPS for the current fiscal year.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.